BOM:500087 (India)
Â
Shs Dematerialised
₹
1,515.95
+10.65 (+0.71%)
Jul 1
Business Description
Cipla Ltd
ISIN : INE059A01026
Share Class Description:
BOM:500087: Shs DematerialisedCompare
Compare
Traded in other countries / regions
500087.IndiaCIPLA.Luxembourg IPO Date
1992-03-02Description
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 25.17 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.06 | |||||
| Interest Coverage | 97.1 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 13.87 | |||||
| Beneish M-Score | -2.22 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.8 | |||||
| 3-Year EBITDA Growth Rate | 20.3 | |||||
| 3-Year EPS without NRI Growth Rate | 27.5 | |||||
| 3-Year FCF Growth Rate | 9.6 | |||||
| 3-Year Book Growth Rate | 14.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 2.75 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 8.16 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 64.69 | |||||
| 9-Day RSI | 58.73 | |||||
| 14-Day RSI | 55.8 | |||||
| 3-1 Month Momentum % | 1.41 | |||||
| 6-1 Month Momentum % | -4.31 | |||||
| 12-1 Month Momentum % | -0.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.25 | |||||
| Quick Ratio | 3.22 | |||||
| Cash Ratio | 2.01 | |||||
| Days Inventory | 224.19 | |||||
| Days Sales Outstanding | 71.11 | |||||
| Days Payable | 108.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.86 | |||||
| Dividend Payout Ratio | 0.2 | |||||
| 3-Year Dividend Growth Rate | 37.5 | |||||
| Forward Dividend Yield % | 0.86 | |||||
| 5-Year Yield-on-Cost % | 0.86 | |||||
| Shareholder Yield % | 1.12 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 67.11 | |||||
| Operating Margin % | 22.18 | |||||
| Net Margin % | 19.42 | |||||
| EBITDA Margin % | 29.43 | |||||
| FCF Margin % | 12.73 | |||||
| ROE % | 18.34 | |||||
| ROA % | 15.1 | |||||
| ROIC % | 20.48 | |||||
| 3-Year ROIIC % | 52.08 | |||||
| ROC (Joel Greenblatt) % | 52.68 | |||||
| ROCE % | 23.31 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 23.07 | |||||
| Forward PE Ratio | 24.29 | |||||
| PE Ratio without NRI | 23.08 | |||||
| Shiller PE Ratio | 43.15 | |||||
| Price-to-Owner-Earnings | 23.67 | |||||
| PEG Ratio | 1.37 | |||||
| PS Ratio | 4.48 | |||||
| PB Ratio | 3.9 | |||||
| Price-to-Tangible-Book | 4.67 | |||||
| Price-to-Free-Cash-Flow | 35.19 | |||||
| Price-to-Operating-Cash-Flow | 24.31 | |||||
| EV-to-EBIT | 16.26 | |||||
| EV-to-Forward-EBIT | 17.75 | |||||
| EV-to-EBITDA | 14.01 | |||||
| EV-to-Forward-EBITDA | 14.69 | |||||
| EV-to-Revenue | 4.12 | |||||
| EV-to-Forward-Revenue | 3.59 | |||||
| EV-to-FCF | 32.14 | |||||
| Price-to-GF-Value | 1.03 | |||||
| Price-to-Projected-FCF | 2.03 | |||||
| Price-to-DCF (Earnings Based) | 1.24 | |||||
| Price-to-DCF (FCF Based) | 1.36 | |||||
| Price-to-Median-PS-Value | 1.28 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.39 | |||||
| Price-to-Graham-Number | 2.2 | |||||
| Price-to-Net-Current-Asset-Value | 7.16 | |||||
| Price-to-Net-Cash | 25.32 | |||||
| Earnings Yield (Greenblatt) % | 6.15 | |||||
| FCF Yield % | 2.82 | |||||
| Forward Rate of Return (Yacktman) % | 16.7 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers